Association of Kaposi's Sarcoma-Associated Herpesvirus-Positive Primary Effusion Lymphoma With Expression of the CD138/Syndecan-1 Antigen

Primary effusion lymphoma (PEL) represents a novel B-cell non-Hodgkin's lymphoma (NHL) type associated with Kaposi's sarcoma-associated herpesvirus infection and typically growing as lymphomatous effusions in the body cavities. The precise B-cell subset from which PEL originates as well as...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1997-12, Vol.90 (12), p.4894-4900
Main Authors: Gaidano, G., Gloghini, A., Gattei, V., Rossi, M.F., Cilia, A.M., Godeas, C., Degan, M., Perin, T., Canzonieri, V., Aldinucci, D., Saglio, G., Carbone, A., Pinto, A.
Format: Article
Language:English
Subjects:
AIDS/HIV
Biological and medical sciences
Hematologic and hematopoietic diseases
Herpesvirus 8, Human - isolation & purification
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma - chemistry
Lymphoma - pathology
Lymphoma - virology
Medical sciences
Membrane Glycoproteins - analysis
Membrane Glycoproteins - genetics
Proteoglycans - analysis
Proteoglycans - genetics
RNA, Messenger - analysis
Syndecan-1
Syndecans
Tumor Cells, Cultured
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary effusion lymphoma (PEL) represents a novel B-cell non-Hodgkin's lymphoma (NHL) type associated with Kaposi's sarcoma-associated herpesvirus infection and typically growing as lymphomatous effusions in the body cavities. The precise B-cell subset from which PEL originates as well as the biologic mechanisms responsible for its peculiar growth pattern are unclear. In this study, we have analyzed PEL for the expression status of CD138/syndecan-1, a molecule selectively associated with late stages of B-cell differentiation and implicated in cell-to-cell and cell-to-extracellular matrix interactions. PEL patient samples (n = 7) and cell lines (n = 5) were investigated by multiple approaches, including immunocytochemistry, flow cytometry, RNA analysis, and Western blot studies. For comparison, lymphomatous effusions other than PEL (n = 13) and tissue-based NHL (n = 103) were also tested. Expression of CD138/syndecan-1 associates at high frequency with PEL (5 of 7 patient samples and 5 of 5 cell lines), whereas it is consistently absent among other lymphomatous effusions (n = 13). The CD138/syndecan-1 isoform expressed by PEL has an average molecular weight of 420 kD, which is substantially different from that of CD138/syndecan-1 molecules generally expressed by plasma cells. These data, along with previous immunophenotypic evidence, unequivocally define that PEL cells represent a preterminal stage of B-cell differentiation and may bear implications for the peculiar growth pattern of this lymphoma.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V90.12.4894